In a landmark decision for public health, South Africa has become the first African nation and only the third country in the world to register a new HIV prevention jab that requires just two injections per year.
The medicine, Lenacapavir, has been hailed as a potential tool to end the country’s HIV/Aids epidemic within 14 to 18 years, provided there is sufficient uptake. The South African Health Products Regulatory Authority (SAHPRA) granted rapid approval for the injection, clearing the path for the national health department to begin distribution.
A spokesperson for the health department confirmed that a rollout could begin as early as February of next year. The initial supply of the jab is being funded by a $30 million grant from The Global Fund to Fight AIDS, Tuberculosis and Malaria. This grant will provide enough doses for approximately 450,000 people, with the rollout planned to be phased in over a two-year period.
However, health officials acknowledge that this initial allocation falls significantly short of the long-term goal. To meet the target of ending AIDS within 18 years, South Africa would require between 1 and 2 million doses annually.
The Lenacapavir jab is considered a revolutionary advancement in HIV prevention. Clinical trials have shown it offers nearly full protection for HIV-negative individuals who weigh 35 kilograms or more against acquiring the virus through sexual transmission.
The need for such a tool is acute in South Africa, which has one of the highest HIV burdens in the world. An estimated 8 million South Africans are living with the virus. The epidemic disproportionately affects young women, with approximately one thousand adolescent girls and young women newly infected every week.
The approval of Lenacapavir offers a new, powerful option in the prevention arsenal, potentially transforming the fight against HIV by reducing the reliance on daily pill regimens.
Â
